Select therapeutic use:

Arthritis/rheumatic disorders:

Indications for TALTZ:

Active psoriatic arthritis. Active ankylosing spondylitis. Active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

Adult:

Give by SC inj into upper arms, thighs, or any quadrant of abdomen; rotate inj sites. ≥18yrs: Psoriatic arthritis: 160mg (two 80mg injs) at Week 0, then 80mg every 4 weeks; may be given alone or in combination with a conventional DMARD. With coexistent plaque psoriasis: 160mg (two 80mg injs) at Week 0, then 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4 weeks. Ankylosing spondylitis: 160mg (two 80mg injs) at Week 0, then 80mg every 4 weeks. nr-axSpA: 80mg every 4 weeks.

Children:

<18yrs: not established.

Warnings/Precautions:

May increase risk of infections. If a serious infection develops, monitor closely and discontinue until resolved. Active TB infection: do not initiate until resolved. Evaluate for TB infection and treat latent TB prior to initiating. Monitor for active TB during and after therapy. History of latent or active TB without confirmed adequate course of treatment: consider anti-TB therapy prior to initiation. Monitor for inflammatory bowel disease; discontinue and treat if occurs. Discontinue immediately and treat if a serious hypersensitivity reaction occurs. Complete all age appropriate immunizations based on current guidelines prior to initiating. Pregnancy. Nursing mothers.

Pharmacologic Class:

Interleukin-17A antagonist.

Interactions:

Avoid concomitant live vaccines. Monitor CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine); consider dose adjustment of these substrates.

Adverse Reactions:

Inj site reactions, upper respiratory tract infections, nausea, tinea infections.

Generic Availability:

NO

How Supplied:

Single-use prefilled autoinjector—1, 2, 3; Single-use prefilled syringe—1

Pricing for TALTZ

1 autoinjector of 80mg/ml carton (Qty: 1)
Appx. price $5644
GoodRx

Psoriasis:

Indications for TALTZ:

Moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.

Adult:

Give by SC inj into upper arms, thighs, or any quadrant of abdomen; rotate inj sites. ≥18yrs: 160mg (two 80mg injs) at Week 0, then 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4 weeks.

Children:

<6yrs: not established. Give by SC inj into upper arms, thighs, or any quadrant of abdomen; rotate inj sites. ≥6yrs (<25kg): initially 40mg (0.5mL) at Week 0, then 20mg (0.25mL) every 4 weeks; (25–50kg): initially 80mg at Week 0, then 40mg every 4 weeks; (>50kg): initially 160mg (two 80mg injs) at Week 0, then 80mg every 4 weeks.

Warnings/Precautions:

May increase risk of infections. If a serious infection develops, monitor closely and discontinue until resolved. Active TB infection: do not initiate until resolved. Evaluate for TB infection and treat latent TB prior to initiating. Monitor for active TB during and after therapy. History of latent or active TB without confirmed adequate course of treatment: consider anti-TB therapy prior to initiation. Monitor for inflammatory bowel disease; discontinue and treat if occurs. Discontinue immediately and treat if a serious hypersensitivity reaction occurs. Complete all age appropriate immunizations based on current guidelines prior to initiating. Pregnancy. Nursing mothers.

Pharmacologic Class:

Interleukin-17A antagonist.

Interactions:

Avoid concomitant live vaccines. Monitor CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine); consider dose adjustment of these substrates.

Adverse Reactions:

Inj site reactions, upper respiratory tract infections, nausea, tinea infections.

Generic Availability:

NO

How Supplied:

Single-use prefilled autoinjector—1, 2, 3; Single-use prefilled syringe—1

Pricing for TALTZ

1 autoinjector of 80mg/ml carton (Qty: 1)
Appx. price $5644
GoodRx